GHRH analog comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-07-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
where Bn is the binding energy of the captured electron. Because the binding energy of the electron is much less than the mass of the electron, nuclei that can undergo β+ decay can always also undergo electron capture, but the reverse is not true.
== Hematopoietic == Acute biphenotypic leukemia Acute eosinophilic leukemia Acute lymphoblastic leukemia Acute myeloid leukemia Acute myeloid dendritic cell leukemia AIDS-related lymphoma Anaplastic large cell lymphoma Angioimmunoblastic T-cell lymphoma B-cell prolymphocytic leukemia Burkitt's lymphoma Chronic lymphocytic leukemia Chronic myelogenous leukemia Cutaneous T-cell lymphoma Diffuse large B-cell lymphoma Follicular lymphoma Hairy cell leukemia Hepatosplenic T-cell lymphoma Hodgkin's lymphoma Intravascular large B-cell lymphoma Large granular lymphocytic leukemia Lymphoplasmacytic lymphoma Lymphomatoid granulomatosis Mantle cell lymphoma Marginal zone B-cell lymphoma Mast cell leukemia Mediastinal large B cell lymphoma Multiple myeloma/plasma cell neoplasm Myelodysplastic syndromes Mucosa-associated lymphoid tissue lymphoma Mycosis fungoides Nodal marginal zone B cell lymphoma Non-Hodgkin lymphoma Precursor B lymphoblastic leukemia Primary central nervous system lymphoma Primary cutaneous follicular lymphoma Primary cutaneous immunocytoma Primary effusion lymphoma Plasmablastic lymphoma Sézary syndrome Splenic marginal zone lymphoma T-cell prolymphocytic leukemia
=== Differential diagnosis === Because catatonia overlaps with many psychiatric and neurological conditions a careful and detailed history, medication review, and physical exam are key to diagnosing catatonia and differentiating it from other conditions. Furthermore, some of these conditions can themselves lead to catatonia. The differential diagnosis is as follows:
Sources: en.wikipedia.org
Muscle glycogen appears to function as a reserve of quickly available phosphorylated glucose, in the form of glucose-1-phosphate, for muscle cells. Glycogen contained within skeletal muscle cells are primarily in the form of β particles. Other cells that contain small amounts use it locally as well. As muscle cells lack glucose-6-phosphatase, which is required to pass glucose into the blood, the glycogen they store is available solely for internal use and is not shared with other cells. This is in contrast to liver cells, which, on demand, readily do break down their stored glycogen into glucose and send it through the blood stream as fuel for other organs. Skeletal muscle needs ATP (provides energy) for muscle contraction and relaxation. Skeletal muscle relies predominantly on glycogenolysis for the first few minutes as it transitions from rest to activity, as well as throughout high-intensity aerobic activity and all anaerobic activity. During anaerobic activity, such as weightlifting and isometric exercise, the phosphagen system (ATP-PCr) and muscle glycogen are the only substrates used as they do not require oxygen nor blood flow. Different bioenergetic systems produce ATP at different speeds, with ATP produced from muscle glycogen being much faster than fatty acid oxidation. The level of exercise intensity determines how much of which substrate (fuel) is used for ATP synthesis also. Muscle glycogen can supply a much higher rate of substrate for ATP synthesis than blood glucose.
All except the Acela, Northeast Regional and Vermonter originate and terminate at Penn Station. Amtrak normally uses tracks 5–12 alongside New Jersey Transit and shares tracks 13–16 with the LIRR and NJ Transit.
Remarkably, the tubeworms hemoglobin (which incidentally is the reason for the bright red color of the plume) is capable of carrying oxygen without interference or inhibition from sulfide, despite the fact that oxygen and sulfide are typically very reactive. In 2005, it was discovered that this is possible due to zinc ions that bind the hydrogen sulfide in the tubeworms hemoglobin, therefore preventing the sulfide from reacting with the oxygen. It also reduces the tubeworms tissue from exposure to the sulfide and provides the bacteria with the sulfide to perform chemoautotrophy. It has also been discovered that tubeworms can metabolize CO2 in two different ways, and can alternate between the two as needed as environmental conditions change. In 1988, research confirmed thiotrophic (sulfide-oxidizing) bacteria in Alviniconcha hessleri, a large vent mollusk. In order to circumvent the toxicity of sulfide, mussels first convert it to thiosulfate before carrying it over to the symbionts. In the case of motile organisms such as alvinocarid shrimp, they must track oxic (oxygen-rich) / anoxic (oxygen-poor) environments as they fluctuate in the environment. Organisms living at the edge of hydrothermal vent fields, such as pectinid scallops, also carry endosymbionts in their gills, and as a result their bacterial density is low relative to organisms living nearer to the vent. However, the scallop's dependence on the microbial endosymbiont for obtaining their nutrition is therefore also lessened.
Sources: en.wikipedia.org
American Heart Association's Heart Attack web site – Information and resources for preventing, recognizing, and treating a heart attack. TIMI Score for UA/NSTEMI Archived 2016-11-05 at the Wayback Machine and STEMI Archived 2009-03-19 at the Wayback Machine HEART Score for Major Cardiac Events Archived 2016-10-28 at the Wayback Machine "Heart Attack". MedlinePlus. U.S. National Library of Medicine.
== Taxonomy == At one time, all yellow or golden chanterelles in western North America had been classified as Cantharellus cibarius. Using DNA analysis, they have since been shown to be a group of related species. In 1997, the Pacific golden chanterelle (C. formosus) and C. cibarius var. roseocanus were identified, followed by C. cascadensis in 2003, C. californicus in 2008, and C. enelensis in 2017. C. cibarius var. roseocanus occurs in the Pacific Northwest in Sitka spruce forests, as well as Eastern Canada in association with Pinus banksiana.
Foods (fava beans is the hallmark trigger for G6PD mutation carriers) Certain medicines including rasburicase, primaquine and other antimalarials[PMID 36049896] Moth balls (naphthalene) Stress from a bacterial or viral infection
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.